| [1] |
Bonadonna G,Brusamolion E,Valagussa P,et al.Combination chemotherapy as an adjuvant treatment in operable breast cancer.N Engl J Med,1976,294:405-410.
|
| [2] |
Bonadonna G,Moliterni A,Zambetti M,et al.30 years'follow up of randomized studies of adjuvant CMF in operable breast cancer:cohort study.BMJ,2005,330:217-220.
|
| [3] |
Early Breast Cancer Trialist's Collaborative Group.Polychemotherapy for early b reast cancer:n overview of the randomized trials.Lancet,1998,352:930-932.
|
| [4] |
Early breast Cancer Trialists'Collaborative Group.Tamoxifen for early breast cancer:an overview of the randomized trials.Lancet,1998,351:1451-1467.
|
| [5] |
Henderson IC,Berry D,Demetri GD,et al.Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.J Clin Oncol,2003,21:976-983.
|
| [6] |
Mamounas EP,Bryant J,Lembersky BC,et al.paclitaxel(T)following d oxorubicin/cyclophosphamide(AC)as adjuvant chemotherapy for node-positive breast cancer:results from NSABP B-28.Proc Am Soc Clin Oncol,2003,22:12.
|
| [7] |
Martin M,Pienkowski T,Mackey J,et al.TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients,BCIRG 001:55 months follow-up.Breast Cancer Res Treat,2003,82:43.
|
| [8] |
Citron M L,Berry D A,Cirrincione C,et al.Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer;first report of intergroup trail C9741/Cancer and leukemia Group B trial 9741.J Clin Oncol,2003,21:1431-1439.
|
| [9] |
Sparano J A,Wang M,Martino S,et al.PhaseⅢstudy of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer:Results of Intergroup Trial E1199.Proc Am Soc Clin Oncol,2007,25:6s.
|
| [10] |
BurnellⅣM J,Levine M N,Chapman J A,et al.A phaseⅢadjuvant trial of sequenced EC+filgrastim+epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer(NCIC CTG MA.21).Proc Am Soc Clin Oncol,2007,25:15s.
|
| [11] |
Romond E H,Perez E A,Bryant J,et al.Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer.New Engl J Med,2005,353:1673-1684.
|
| [12] |
Rastogi P,Jeong J,Geyer C E,et al.Five year update of cardiac dysfunction on NSABP B-31,a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel(T)vs.AC→T with trastuzumab(H).Proc Am Soc Clin Oncol,2007,25:964s.
|
| [13] |
Piccart Gebhart M J,Protcer M,Leyland Jones B,et al.Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer.New Engl J Med,2005,353:1660-1672.
|
| [14] |
Smith M,Procter R,Gelber S,et al.2-year follow-up of trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer:a randomised controlled trial.Lancet,2007,369:29-36.
|
| [15] |
Ingle J N,Dowsett M,Cuzick J,et al.Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer:meta-analyses of randomized trials of monotherapy and switching strategies.Cancer Res,2009,69:66s.
|
| [16] |
Dent R,Trudeau M,Pritchard K I,et al.Triple-negative breast cancer:Clinical features and patterns of recurrence.Clin Cancer Res,2007,13:4429-4434.
|
| [17] |
Bauer K R,Brown M,Cress R D,et al.Descriptive analysis of estrogen receptor (ER)-negative,and HER-2-negative invasive breast cancer,the so-called triple -negative phenotype:a population-based study from the California Cancer Registry.Cancer,2007,109:1721-1728.
|
| [18] |
Carey L A,Dees EC,Sawyer L,et al.The triple negative paradox:Primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res,2007,13:2329-2334.
|
| [19] |
Haffty B G,Yang Q,Reiss M,et al.Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.J Clin Oncol,2006,24:5652-5657.
|
| [20] |
Brenton J D,Carey L A,Ahmed A A,et al.Molecular classification and molecular forecasting of breast cancer:ready for clinical application?J Clin Oncol,2005,23:7350-7360.
|
| [21] |
Nielsen T O,Hsu F D,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.Clin Cancer Res,2004,10:5367-5374.
|
| [22] |
Gholam D,Chebib A,Hauteville D,et al.Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive,estrogen receptor-negative,progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative)breast cancer.Anticancer Drugs,2007,18:835-837.
|
| [23] |
Fan C,Oh D S,Wessels L,et al.Concordance among gene-expression-based predictors for breast cancer.N Engl J Med,2006,355:615-617.
|
| [24] |
van de Vijver M J,He Y D,van't Veer L J,et al.A gene-expression signature as a predictor of survival in breast cancer.N Engl J Med,2002,347:1999-2009.
|
| [25] |
Park S,Shak S,Tang G,et al.A multigene assay to predict recurrence of tamoxifen-treated,node-negative breast cancer.N Engl J Med,2004,351:2817-2826.
|
| [26] |
Habel L A,Shak S,Jacobs M K,et al.A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.Breast Cancer Res,2006,8:R25.
|
| [27] |
Park S,Tang G,Shak S,et al.Gene expression and benefit of chemotherapy in women with node-negative,estrogen receptor-positive breast cancer.J Clin Oncol,2006,24:3726-3734.
|
| [28] |
Mamounas E T G,Bryant J,Paik S,et al.Association between the 21-gene recurrence score(RS)assay and risk of loco-regional failure in node-negative,er-positive breast cancer:Results from NSABP B-14 and NSABP B-20.Breast Cancer Res,2005,94:S16.
|